Home › Cardiovascular Scores, Indexes, And Algorithms › TWILIGHT-HF Subgroup Analysis Score

TWILIGHT-HF Subgroup Analysis Score

  • Age (years)
  • Sex
  • Presentation
  • Diabetes mellitus
  • Chronic kidney disease (eGFR <60 ml/min/1.73m²)
  • Anemia (known low hemoglobin)
  • Exploratory TWILIGHT-HF Subgroup Analysis Score: Explanation and context
    The TWILIGHT randomized trial tested whether, among high-risk patients who had completed 3 months of dual antiplatelet therapy after PCI, stopping aspirin and continuing ticagrelor monotherapy reduced clinically relevant bleeding without increasing ischemic events. The trial found a lower rate of BARC 2/3/5 bleeding with ticagrelor monotherapy versus ticagrelor plus aspirin, with ischemic outcomes noninferior across the whole study population. Subgroup analyses (preplanned and post-hoc) assessed consistency of the bleeding/ischemic effects across groups defined by age, sex, diabetes, ACS status and other baseline variables. This tool aggregates a small set of those subgroup variables into a transparent point count to illustrate relative subgroup burden; it is not a replication of a published predictive score and does not produce validated absolute risk predictions.

    Reference:
    Mehran R, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381:1309–1320.
    Additional prespecified and subgroup analyses and commentaries: sex and subgroup analyses (see listed publications and meeting presentations).

Discussion

No discussions yet. Be the first to comment.

Report this Tool